Zhang, Su-Zhen
Mu, Yong-Gang
Liu, Qi
Shi, Ying
Guo, Li-Hua
Li, Ling-Zhi
Yang, Fu-De
Wang, Yong
Li, Tao
Mei, Qi-Yi
He, Hong-Bo
Chen, Zhi-Yu
Su, Zhong-Hua
Liu, Tie-Bang
Xie, Shi-Ping
Tan, Qing-Rong
Zhang, Jin-Bei
Zhang, Cong-Pei
Sang, Hong
Mi, Wei-Feng
Zhang, Hong-Yan
Funding for this research was provided by:
Capital Health Development Research (2016-2-4112)
Beijing Municipal Commission of Science and Technology Clinical Application Special Fund (Z181100001718157)
National Science and Technology Major Project for IND (investigational new drug (2018ZX09734-005)
Article History
Received: 15 January 2019
Accepted: 23 June 2019
First Online: 10 July 2019
Ethics approval and consent to participate
: The study protocol was approved by the ethics committees of Peking University Sixth Hospital and all other participating hospitals. Patients themselves or their legal guardians (if involuntary admission) had signed their informed consent of the study.
: Not applicable.
: The authors declare that they have no competing interests.